King & Wood Mallesons acted for Humanwell Healthcare (Group) Co., Ltd, a Shanghai listed healthcare company, and CITIC Capital on their US$600 million acquisition of ASX-listed Ansell Limited's sexual wellness business.
Ansell's Sexual Wellness Business manufactures and sells a wide variety of products across the world, including high quality condoms, lubricants, feminine hygiene products and vibrating devices under the Skyn, Lifestyles, Zero, Manix, Blowtex and Jissbon brands.
King & Wood Mallesons acted as global counsel for the transaction involving the incorporation and purchase of companies in China, Singapore, Thailand, India, Australia, UK, USA and Poland and the transfer of intellectual property, employees, medical registrations and assets from all over the world into various acquisition vehicles. King & Wood Mallesons negotiated and managed sale documentation, debt and equity funding and shareholder arrangements, managed local counsel in over 10 jurisdictions and dealt with regulatory approval with PRC authorities and FIRB.
The King & Wood Mallesons deal team was led by Partners David Friedlander, Lee Horan, Scott Bouvier and Special Counsel Matt Egerton-Warburton. They were supported by Senior Associates Clifford Sandler and Melissa Miller, Solicitors Robert Garritano, Stephanie Daaboul, Vishaal Sharma, Lauren Chape, Yixin Gong and Maggie Chan.
The King & Wood Mallesons PRC team was led by Partner Han Xue and Senior Associate Yingyuan Xue. The King & Wood Mallesons Singapore team was led by Partner Michael Lawson and Senior Associate Tian Xu.
Commenting on the announcement, David Friedlander said: "This deal showcased the power of the firm to work alongside Nomura to manage and deliver a difficult, global transaction involving significant amounts of global intellectual property in a highly regulated industry. We are grateful for the opportunity of supporting Humanwell and Citic Capital and we look forward to continuing to support them with this and future transactions."
Humanwell Healthcare (Group) Co., Ltd was founded in 1993 and is headquartered in China. It is listed on the Shanghai Stock Exchange with a market capitalization of US$3.5 Billion and an active presence in over 10 countries with 13,000 employees worldwide. Humanwell is a leader in several healthcare market segments and is one of the largest providers of anesthetics, fertility regulation and Uyghur Medicine in Asia.
Citic Capital Partners is the private equity arm of CITIC Capital and currently manages US$4.5 Billion of committed capital. Citic Capital invests and manages funds on behalf of a diverse group of international and Chinese investors with an emphasis on China, Japan and the US.
